Document:

<PAGE>   1

                                                                   EXHIBIT 10.14

                                [ANTIGENICS LOGO]
                                   ANITGENICS

                                                     November 15, 1999

Medison Pharma Ltd.
10 Hashiloach St. P.O.B. 7090
Petach-Tikva 49170
Israel

Dear Mr. Jakobsohn:

We refer to our recent discussions regarding a potential Licensing and
Distribution Relationship between Antigenics LLC ("Antigenics") and Medison
Pharma Ltd. ("Medison") in Israel with regard to Antigenics' proprietary
technology utilizing Heat Shock Proteins ("HSP") for the boosting and modulating
of the immune system of humans against cancer (the "Technology").

The following outline the general terms and conditions of a Licensing and
Distribution Relationship:

         1.   Antigenics' shall grant Medison a license for the Technology in
              Israel solely for the purposes outlined in this Letter Agreement.
         2.   In each of Antigenics' Phase III Trials, Antigenics will include a
              limited number of clinical sites in Israel. Antigenics' obligation
              will cease if it is determined by both companies that there are
              insufficient sites available to accrue the appropriate number of
              patient's according to Antigenics' timelines.
         3.   All data, clinical and otherwise, generated in the Israeli sites
              will be property of Antigenics.
         4.   Medison shall be Antigenics' exclusive sales and marketing agent
              for the Israeli market.
         5.   For the Israeli market, Medison will be responsible, at its own
              costs, for preparing and filing all regulatory documents and
              providing whatever support is necessary to obtain regulatory
              approval in Israel.
         6.   Medison shall be responsible for obtaining any necessary
              reimbursement approvals.

<PAGE>   2

         7.   After regulatory approval, Medison shall be responsible for all
              sales and marketing efforts and expenses.
         8.   Antigenics shall receive 45% of Net Sales and Medison shall
              receive 55% of Net Sales.
         9.   Medison and its affiliates shall make an equity investment of
              $350,000 in Antigenics LLC 1999 Private Placement and will be
              entitled to all the rights granted to the other investors as
              detailed in the Private Placement Memorandum dated 8/31/99, the
              Subscription Agreement and the Limited Liability Company
              Agreement.
         10.  Your rights and obligations will be subject to typical termination
              provisions, however, the Agreement will not contain a change in
              control termination provision.
         11.  The term of the agreement shall be 7 years.

Prior to the initiation of Antigenics' first Phase III trial in cancer,
Antigenics and Medison shall negotiate and sign a License and Distribution
Agreement acceptable to both parties. That agreement shall contain terms and
conditions typical to for an agreement of that type, including appropriate
termination provisions and best efforts clauses.

This Letter Agreement shall be governed by and construed and enforced in
accordance with the laws of the state of New York, without regard to the
conflicts of law principles thereof. In the event of any dispute, New York
courts shall have exclusive jurisdiction of such dispute.

If the foregoing correctly expresses our understanding, please so indicate by
signing and dating the enclosed copy of this Letter Agreement and returning it
to the undersigned.

Sincerely,

Antigenics LLC

By:    /s/ Garo H. Armen
       ------------------------------------
Name:  Garo H. Armen
       ------------------------------------

Title: Chairman and Chief Executive Officer
       ------------------------------------

<PAGE>   3

Medison

By:    /s/  Mier Jakobsohn        /s/  Shmuel Berkovich
       ------------------------
Name:  /s/  Mier Jakobsohn        /s/  Shmuel Berkovich
       ------------------------
Title: General Manager            General Manager
       ------------------------Exhibit 4.1 (2)
  NOT VALID UNLESS COUNTERSIGNED BY TRANSFER AGENT INCORPORATED UNDER THE LAWS
                             OF THE STATE OF NEVADA

                       INCORPORATED IN THE STATE OF NEVADA

NUMBER                                                                    SHARES

                               IKON VENTURES, INC.
                         100,000,000 AUTHORIZED SHARES
                           PAR VALUE: $.001 PER SHARE          CUSIP 451714 10 9

THIS CERTIFIES THAT

IS THE RECORD HOLDER OF

                               IKON VENTURES, INC.

  transferable on the books of the Corporation in person or by duly authorized
attorney upon surrender of this Certificate properly endorsed. This Certificate
  is not valid until countersigned by the Transfer Agent and registered by the
                                   Registrar.

   Witness the facsimile seal of the Corporation and the facsimile signatures
                        of its duly authorized officers.

Dated:

---------------------------------            -----------------------------------
         SECRETARY                                         PRESIDENT

                                                  Countersigned & Registered:
                                                  MADISON STOCK TRANSFER, INC.
                                                  P.O. BOX 290-145
                                                  Brooklyn, NY 11229-0145

                                                  By:
                                                      --------------------------

                               IKON VENTURES, INC.

                                CORPORATE NEVADA

                                 CORPORATE SEALExhibit 4.1 (3)

        ________________________________________________________________

                        WARRANT TO PURCHASE COMMON STOCK

                                       OF

                               IKON VENTURES, INC.

         _______________________________________________________________

                   THIS WARRANT AND THE SHARES OF COMMON STOCK
                     ISSUABLE PURSUANT TO THIS WARRANT HAVE
              NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
                  AS AMENDED (THE "ACT"), AND MAY NOT BE SOLD,
                     PLEDGED OR OTHERWISE TRANSFERRED UNLESS
                  REGISTERED UNDER THE ACT OR AN EXEMPTION FROM
                         SUCH REGISTRATION IS AVAILABLE.

         FOR VALUE  RECEIVED,  Ikon Ventures,  Inc., a Nevada  corporation  (the
"Company"),  grants  the  following  rights to  ___________________  , having an
address at __________________ ("Holder").

ARTICLE 1.        DEFINITIONS.  As used herein, the following  terms  shall have
the following  meanings,  unless the context shall otherwise require:

                  (a) "Common Stock" shall mean the common stock, par value $.01
per share, of the Company.

                  (b)  "Corporate  Office"  shall mean the office of the Company
(or its successor) at which at any particular time its principal  business shall
be  administered,  which  office is  located at the date  hereof at 5  Craysfort
House, 14 West Halkin Street, London SW1X 8JS, England..

                  (c) "Exercise  Date" shall mean any date upon which the Holder
shall give the Company a Notice of Exercise.

                  (d)  "Exercise  Price"  shall mean the price to be paid to the
Company for each share of Common  Stock to be  purchased  upon  exercise of this
Warrant in accordance with the terms hereof which shall be $7.50.

                  (e) "Expiration  Date" shall mean 5:00 p.m. (New York time) on
_______ 2000.

<PAGE>

                  (f) "SEC" shall mean the United States Securities and Exchange
Commission.

ARTICLE 2.        EXERCISE.

         2.1      Exercise of Warrant.  This  Warrant  shall  entitle  Holder to
purchase up to ___________ shares of Common Stock (the "Shares") at the Exercise
Price. This Warrant shall be exercisable at any time and from time to time prior
to the Expiration  Date (the "Exercise  Period").  This Warrant and the right to
purchase Shares hereunder shall expire and become void at the Expiration Date.

         2.2      Acceleration  of Exercise  Period.  The Company shall have the
right, at any time after the Common Stock has traded for twenty-one  consecutive
days with a daily  closing bid price of $10.00 or more per share,  to accelerate
the Exercise  Period by sending to the Holder,  at the Holder's  address written
above, a Notice of Acceleration in substantially the form attached as Appendix I
hereto (the  "Notice").  In the event the Company does  accelerate  the Exercise
Period,  the Holder  shall have ten (10) days from the date the Holder  receives
the Notice within which to exercise  this Warrant in the manner  provided for in
Section 2.3,  after which time this Warrant and the right to purchase the Shares
hereunder, to the extent not previously exercised, shall expire and become void.
The Holder  shall be deemed to have  received the Notice five (5) days after the
date the Notice is deposited in the U.S. Mails.

         2.3      Manner of Exercise.

                  (a) Holder may exercise this Warrant at any time and from time
to  time  during  the  Exercise  Period,  in  whole  or  in  part  (but  not  in
denominations  of fewer than  2,500  Shares,  except  upon an  exercise  of this
Warrant with respect to the remaining balance of Shares purchasable hereunder at
the time of exercise),  by delivering to the Company at its Corporate Office (i)
a duly  executed  Notice of  Exercise  in  substantially  the form  attached  as
Appendix  II  hereto  and  (ii) a bank  cashier's  or  certified  check  for the
aggregate Exercise Price of the Shares being purchased.

                  (b) From time to time upon exercise of this Warrant,  in whole
or part, in accordance with its terms, the Company will cause its transfer agent
to countersign  and deliver stock  certificates to the Holder  representing  the
number  of  Shares  being  purchased  pursuant  to  such  exercise,  subject  to
adjustment as described herein.

                  (c) Promptly  following any exercise of this  Warrant,  if the
Warrant has not been fully  exercised  and has not  expired,  the  Company  will
deliver  to the Holder a new  Warrant  for the  balance  of the  Shares  covered
hereby.

         2.4      Termination.  All rights of the Holder in this Warrant, to the
extent they have not been exercised, shall terminate on the Expiration Date.

         2.5      No Rights Prior to Exercise. Prior to its exercise pursuant to
Section 2.3 above,  this  Warrant  shall not entitle the Holder to any voting or
other rights as holder of Shares.

<PAGE>

         2.6      Adjustments.   In  case  of  any   reclassification,   capital
reorganization,  stock dividend or other change of outstanding  shares of Common
Stock,  or in case of any  consolidation  or merger of the Company  with or into
another  corporation  (other than a consolidation or merger in which the Company
is the continuing corporation and which does not result in any reclassification,
capital reorganization,  stock dividend or other change of outstanding shares or
Common  Stock),  or in case of any sale or conveyance to another  corporation of
the property of the Company as, or  substantially  as, an entirety (other than a
sale/leaseback,  mortgage or other  financing  transaction),  the Company  shall
cause  effective  provision  to be made so that the Holder  shall have the right
thereafter,  by  exercising  this  Warrant,  to purchase  the kind and number of
shares of stock or other securities or property (including cash) receivable upon
such reclassification,  capital reorganization,  stock dividend or other change,
consolidation, merger, sale or conveyance as the Holder would have been entitled
to receive had the Holder exercised this Warrant in full immediately before such
reclassification,  capital  reorganization,  stock  dividend  or  other  change,
consolidation,  merger,  sale or conveyance.  Any such  provision  shall include
provision  for  adjustments  that  shall  be as  nearly  equivalent  as  may  be
practicable to the  adjustments  provided for in this Section 2.5. The foregoing
provisions  shall  similarly  apply  to  successive  reclassifications,  capital
reorganizations,  stock  dividends  and other changes of  outstanding  shares of
Common Stock and to successive consolidations, mergers, sales or conveyances.

         2.7      Fractional Shares. No fractional Shares shall be issuable upon
exercise  or  conversion  of this  Warrant and the number of Shares to be issued
shall be rounded down to the nearest whole Share. If a fractional Share interest
arises upon any  exercise  or  conversion  of the  Warrant,  the  Company  shall
eliminate such fractional Share interest by paying Holder the amount computed by
multiplying the fractional  interest by the closing bid price of a full Share on
the date of the Notice of Exercise.

ARTICLE 3.        REPRESENTATIONS AND COVENANTS OF THE COMPANY.

         3.1      Representations and Warranties.  The Company hereby represents
and warrants to the Holder as follows:

                  (a) All Shares  which may be issued  upon the  exercise of the
purchase  right  represented  by this  Warrant  shall,  upon  issuance,  be duly
authorized, validly issued, fully-paid and nonassessable,  and free of any liens
and  encumbrances  except for  restrictions  on transfer  provided for herein or
under  applicable  federal  and state  securities  laws,  and not subject to any
pre-emptive rights.

                  (b) The Company is a  corporation  duly  organized and validly
existing  under  the laws of the  State of  Nevada,  and has the full  power and
authority  to issue  this  Warrant  and to  comply  with the terms  hereof.  The
execution, delivery and performance by the Company of its obligations under this
Warrant,  including,  without  limitation,  the  issuance of the Shares upon any
exercise of the Warrant have been duly  authorized  by all  necessary  corporate
action.  This Warrant has been duly executed and delivered by the Company and is
a valid and binding  obligation of the Company,  enforceable in accordance  with
its  terms,  except as  enforcement  may be limited  by  applicable  bankruptcy,
insolvency,   reorganization   or  similar  laws  affecting   enforceability  of

<PAGE>

creditors'  rights  generally  and except as the  availability  of the remedy of
specific enforcement,  injunctive relief or other equitable relief is subject to
the discretion of the court before which any proceeding therefor may be brought.

                  (c) The Company is not subject to or bound by any provision of
any  certificate  or articles of  incorporation  or by-laws,  mortgage,  deed of
trust,  lease, note, bond,  indenture,  other instrument or agreement,  license,
permit, trust,  custodianship,  other restriction or any applicable provision of
any law,  statute,  judgment,  order,  writ,  injunction or decree of any court,
governmental body, administrative agency or arbitrator which could prevent or be
violated by or under which there would be a default (or right of termination) as
a result of the  execution,  delivery  and  performance  by the  Company of this
Warrant.

ARTICLE 4.        MISCELLANEOUS.

         4.1      Transfer.  This Warrant may not be transferred or assigned, in
whole or in part, at any time, except in compliance with applicable  federal and
state securities laws by the transferor and the transferee  (including,  without
limitation,  the  delivery of an  investment  representation  letter and a legal
opinion reasonably satisfactory to the Company),  provided that this Warrant may
not be  transferred  or assigned  such that either the Holder or any  transferee
will,  following  such transfer or  assignment,  hold a Warrant for the right to
purchase fewer than 2,500 Shares.

         4.2      Transfer Procedure.  Subject to the provisions of Section 5.1,
Holder may transfer or assign this Warrant by giving the Company  notice setting
forth the name, address and taxpayer  identification number of the transferee or
assignee, if applicable (the "Transferee"), and surrendering this Warrant to the
Company for  reissuance  to the  Transferee  (and the Holder,  in the event of a
transfer  or  assignment  of this  Warrant  in part).  (Each of the  persons  or
entities in whose name any such new Warrant shall be issued are herein  referred
to as a Holder").

         4.3      Loss, Theft, Destruction or Mutilation.  If this Warrant shall
become mutilated or defaced or be destroyed,  lost or stolen,  the Company shall
execute  and  deliver a new  Warrant  in  exchange  for and upon  surrender  and
cancellation  of  such  mutilated  or  defaced  Warrant  or,  in  lieu of and in
substitution  for such  Warrant so  destroyed,  lost or stolen,  upon the Holder
filing with the Company  evidence  satisfactory to it that such Warrant has been
so mutilated,  defaced, destroyed, lost or stolen. However, the Company shall be
entitled,  as a condition to the execution and delivery of such new Warrant,  to
demand  indemnity  satisfactory  to it and payment of the  expenses  and charges
incurred in  connection  with the delivery of such new  Warrant.  Any Warrant so
surrendered to the Company shall be cancelled.

         4.4      Notices. All notices and other communications from the Company
to the Holder or vice versa shall be deemed  delivered and effective  when given
personally,  by  facsimile  transmission  and  confirmed in writing or mailed by
first-class registered or certified mail, postage prepaid at such address and/or
facsimile number as may have been furnished to the Company or the Holder, as the
case may be, in writing by the Company or the Holder from time to time.

<PAGE>

         4.5      Waiver.  This  Warrant  and any term  hereof  may be  changed,
waived,  or  terminated  only by an  instrument  in writing  signed by the party
against which  enforcement of such change,  waiver,  discharge or termination is
sought.

         4.6      Governing Law. This Warrant shall be governed by and construed
in accordance with the laws of the State of the Company's incorporation, without
giving effect to its principles regarding conflicts of law.

Dated:  _______________, 1997

Attest:

                                              IKON VENTURES, INC.

                                              By: ______________________________

                                              Name: ____________________________

                                              Title: ___________________________

<PAGE>

                                                                      APPENDIX I

                             NOTICE OF ACCELERATION

                                              Dated:     _______________________

Ikon Ventures,  Inc. (the  "Company")  does hereby notify you of its election to
exercise its right, pursuant to Section 2.2 of the Warrants issued to you by the
Company on _________, 1997 (the "Warrant"), to accelerate the exercise period of
such  Warrants.  Please be advised that you have ten (10) days from the date you
receive this Notice of  Acceleration  (the  "Ten-Day  Period") to exercise  your
Warrants in the manner provided for in the Warrants.  You will be deemed to have
received  this  Notice of  Acceleration  five (5) days after the above date when
this Notice of Acceleration was first deposited in the U.S. Mails.

You will automatically forfeit your right to purchase the shares of common stock
issuable upon exercise of such Warrants, to the extent not previously purchased,
unless the Warrants are exercised before the end of the Ten-Day Period.

                                                  Ikon Ventures, Inc.

                                                  By: __________________________

                                                  Name: ________________________

                                                  Title: _______________________

<PAGE>

                                   APPENDIX II

                               NOTICE OF EXERCISE

         1. The  undersigned  hereby  elects to  purchase  ______  shares of the
Common  Stock of Ikon  Ventures,  Inc.  pursuant  to the  terms of the  attached
Warrant,  and tenders  herewith  payment of the purchase price of such shares in
full.

         2. Please issue a certificate or certificates  representing said shares
in the name of the undersigned or in such other name as is specified below:

                    _________________________________________________
                                     (Name)

                    _________________________________________________
                                    (Address)

         3. The undersigned represents it is acquiring the shares solely for its
own  account and not as a nominee for any other party and not with a view toward
the  resale  or  distribution  thereof  except  in  compliance  with  applicable
securities laws.

                               _________________________________________________
                                       (Signature)

_______________________
        (Date)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}]]